One of the main challenges oncologists face in the care of patients with lung cancer is the decision to incorporate new clinical trial data into routine clinical practice. Beyond the question of statistical significance, which is a more objective metric, are the results meaningful and applicable to a broader population? Furthermore, in an era of value care, do the results justify a potential increase in costs? This article discusses the main points that clinicians consider in their decision-making process and illustrates the arguments with real-life examples.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e420 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!